Earnings Call Intelligence Subscribe
Home › Call Sheets › BDX › Q1'26
Call sheet · Q1'26

Becton, Dickinson (BDX)

Q1'26 earnings call · held February 9, 2026 · compared with the Q4'25 call · management-credibility review
11/12
Disclosure score
3 medium, 4 low flags
Financial quality
Bottom line
The sleeper story is commercial transformation: Polen isn't just reshaping the portfolio, he's systematically applying BD Excellence methodology to sales for the first time with measurable early results (85% Pyxis Pro competitive wins, record Alaris share gains). The obvious headline is Waters closing with $4B cash, but the real catalyst is this commercial excellence initiative targeting the 90% of New BD already growing mid-single digits. The binding constraint isn't demand but execution speed of these commercial investments in high-margin areas. As Polen said: 'We view that same opportunity exists commercially, and when we execute that, that will deliver higher growth.' My view changes if commercial productivity metrics disappoint or if the China/vaccine headwinds spread beyond the contained 10% of the portfolio.

The 30-second version

  • SLEEPER STORY: Commercial excellence is the real catalyst, not just portfolio reshaping
  • Waters RMT closes TODAY, $4B cash incoming with $2B immediate ASR
  • Three known headwinds are fully contained to 10% of portfolio

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$5.9B (+7.0% YoY)$5.3B (+0.4% YoY)Decelerated 660 bps, expected given RMT structure
New BD Revenue Growth4.9% organic2.5% FX-neutralDecelerated 240 bps but in line with guided headwinds
Adjusted EPS$3.96$2.91Down 15.2% but beat expectations, tariff impact prominent
Adjusted Gross Margin54.2%53.4%Down 80 bps, 170 bps tariff hit partially offset by productivity
Adjusted Operating Margin25.8%21.2%Down 460 bps, tariffs and commercial investments as expected
Free Cash Flow$2.7B full year$548MQ1 conversion improved to 66% vs 59% prior year
APM GrowthDouble-digit pro formaHigh single-digitSlight deceleration but adding 15% more sales force
PureWick GrowthDouble-digitDouble-digitSustained momentum, VA reimbursement expanding addressable market
Biologics GrowthHigh single-digitDouble-digitAccelerated, now 80+ GLP-1 molecules contracted
Alaris Competitive WinsStrong momentumRecord quarter, +100 bps market shareBest competitive performance since relaunch

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full BDX Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.